3
Participants
Start Date
February 24, 2022
Primary Completion Date
July 27, 2022
Study Completion Date
July 27, 2022
C2i Test
The C2i-Test, a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS)-based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD).
New Jersey Urology, Bloomfield
Lead Sponsor
New Jersey Urology
UNKNOWN
University of Texas
OTHER
Baylor College of Medicine
OTHER
NY Health d/b/a New York Cancer and Blood Specialists
OTHER
The Cleveland Clinic
OTHER
Fox Chase Cancer Center
OTHER
New York University
OTHER
University of Washington
OTHER
Oregon Health and Science University
OTHER
University of Southern California
OTHER
Ohio State University
OTHER
C2i Genomics
INDUSTRY